EDAP TMS S.A. entered into an underwriting agreement for an underwritten public offering of 8,425,000 American Depositary Shares at $4.75 per ADS, generating approximately $37.1 million in net proceeds after discounts and expenses. The company granted underwriters a 30-day option to purchase up to an additional 1,263,750 ADSs. Proceeds will fund operating costs, capital expenditures, and general corporate purposes. Executive officers and directors agreed to 90-day lock-up restrictions on their shares. EDAP TMS S.A. operates in the medical technology industry, developing minimally invasive treatments for prostate cancer.
